Cardio Diagnostics Holdings, Inc. to Showcase Data Highlighting PrecisionCHD's Capability to Identify INOCA and MINOCA at the American Heart Association Scientific Sessions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Should l Buy CDIO?
Source: Newsfilter
Underdiagnosed Heart Conditions: Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are significant yet often undetected forms of heart disease, affecting a large number of patients, particularly women.
PrecisionCHD Test Presentation: Cardio Diagnostics will present new data at the AHA Scientific Sessions showcasing how their PrecisionCHD test, which utilizes epigenetic biomarkers, can effectively detect INOCA and MINOCA, providing a noninvasive diagnostic tool.
Research Findings: A study conducted with the University of Iowa demonstrated that DNA methylation markers in the PrecisionCHD test can sensitively and specifically identify INOCA presentations, offering personalized insights for patient care.
Advancing Cardiovascular Medicine: Cardio Diagnostics aims to revolutionize cardiovascular diagnostics through their AI-driven technology, making detection and management of heart disease more accessible and tailored to individual patient needs, especially for underserved populations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDIO
About CDIO
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
Cardio Diagnostics to Host Investor Call on February 19, 2026
- Investor Conference Call: Cardio Diagnostics will host an investor conference call on February 19, 2026, at 3 p.m. Central Time, aimed at providing updates on the company's advancements in cardiovascular disease prevention and early detection.
- Product Updates: The call will cover the latest clinical data and reimbursement progress for the company's existing tests, Epi+Gen CHD™ and PrecisionCHD™, showcasing its innovative capabilities in precision cardiovascular medicine.
- Technology-Driven Approach: Cardio Diagnostics leverages artificial intelligence and genomics to make cardiovascular disease prevention, detection, and management more personalized and precise, further advancing the development and commercialization of clinical tests.
- Risk Factors Disclosure: The company notes in its statement that its future growth strategy may face various known and unknown risks and uncertainties, which could significantly impact its financial performance.
See More
Cardio Diagnostics to Host Investor Conference Call
- Investor Conference Call: Cardio Diagnostics will host an investor conference call on February 18, 2026, at 3 p.m. Central Time, aimed at providing updates on the company's advancements in cardiovascular disease prevention and early detection, particularly regarding its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™.
- Clinical Data Updates: The call will cover recent breakthrough clinical data and reimbursement progress, indicating the company's efforts to enhance the efficiency of cardiovascular disease detection and management through its precision molecular approach.
- Strategic Growth Initiatives: The conference will also discuss the company's strategic growth initiatives, emphasizing its market positioning and future development direction in the field of precision cardiovascular medicine, aimed at attracting more investor interest.
- Webcast Information: Investors can participate via the provided webcast link, while telephone participants should dial the specified numbers and use the provided passcode, ensuring broad dissemination of information and engagement.
See More
Cardio Diagnostics Partners with India to Launch PrecisionCHD Coronary Test
- International Expansion: Cardio Diagnostics has partnered with Aimil Ltd. and Dr. Lal PathLabs Ltd. to introduce the PrecisionCHD coronary test in India, marking the company's first expansion outside the U.S. and targeting a market with rising heart disease rates.
- Technological Innovation: The PrecisionCHD test combines epigenetics, genetics, and AI to detect coronary heart disease at a molecular level from blood samples, addressing the urgent screening demand in urban areas of India where heart disease rates can reach as high as 13%, filling a gap left by traditional angiograms.
- Clinical Integration Progress: The partners have begun integrating the test into Dr. Lal PathLabs' clinical and lab network, with broader commercial deployment expected in 2026 under Indian clinical guidelines, enhancing access to advanced heart diagnostics.
- Executive Insights: Cardio Diagnostics CEO Dr. Meesha Dogan stated that the partnership advances equitable access to cutting-edge cardiovascular care, while Aimil's Executive Director Dr. Mallika Kapoor emphasized that this venture strengthens India's access to advanced heart diagnostics.
See More
Cardio Diagnostics Launches PrecisionCHD Test in India with Aimil and Dr. Lal PathLabs
- Market Expansion: Cardio Diagnostics Holdings partners with Aimil Ltd. and Dr. Lal PathLabs Ltd. to launch the PrecisionCHD test, marking the company's first expansion outside the U.S. and official entry into the Indian market, which is crucial given the rising prevalence of cardiovascular diseases.
- Technological Innovation: The PrecisionCHD test can identify non-obstructive coronary heart disease, surpassing traditional angiography, thereby enabling doctors to provide personalized treatment plans that enhance the quality and effectiveness of healthcare services.
- Commercial Outlook: The test is expected to be commercially launched in 2026, with initial promotion through Dr. Lal PathLabs' laboratory and clinical network, a strategy that will facilitate rapid adaptation to Indian clinical and regulatory protocols, thereby increasing market acceptance.
- Market Reaction: Following the announcement, CDIO's stock surged 29.61% in pre-market trading, indicating a positive market response to this strategic partnership and reflecting investor confidence in the company's future growth potential.
See More
Applied Optoelectronics Reports Strong Q4, Shares Surge
- Earnings Beat: Applied Optoelectronics reported a fourth-quarter loss of only $0.01 per share, significantly better than the analyst consensus estimate of a $0.11 loss, indicating improvements in cost management and market demand, which boosts investor confidence.
- Strong Sales Performance: The company achieved quarterly sales of $134.274 million, surpassing the analyst consensus estimate of $134.120 million, suggesting that its products continue to gain competitive traction in the market, potentially driving future revenue growth.
- Stock Surge: Following the earnings report, Applied Optoelectronics shares jumped 20.4% to $64.69 in pre-market trading, reflecting market optimism about the company's future performance and likely attracting more investor interest.
- Positive Guidance: The company issued first-quarter sales guidance above market expectations, further solidifying its market position in the optoelectronics sector and indicating stable growth potential for the upcoming quarters.
See More
Etsy Sells Depop to eBay for $1.2 Billion
- Significant Transaction Value: Etsy has entered into a definitive agreement with eBay to sell its fashion marketplace Depop for approximately $1.2 billion in cash, which not only provides Etsy with substantial cash flow but also enhances its financial flexibility to support future strategic investments.
- Stock Price Surge: Etsy's shares jumped 15.5% to $50.86 in pre-market trading, reflecting a positive market reaction to the deal and increasing investor confidence in the company's future growth potential.
- Market Consolidation Trend: This transaction signifies further consolidation in the e-commerce sector, as eBay's acquisition of Depop will expand its influence in the fashion market, while Etsy can focus on its core business to improve operational efficiency.
- Strategic Focus Shift: By selling Depop, Etsy can reallocate resources to concentrate on growth within its primary platform, with expectations to drive long-term profitability through optimizing product lines and enhancing user experience.
See More
Cardio Diagnostics to Host Investor Call on February 19, 2026
- Investor Conference Call: Cardio Diagnostics will host an investor conference call on February 19, 2026, at 3 p.m. Central Time, aimed at providing updates on the company's advancements in cardiovascular disease prevention and early detection.
- Product Updates: The call will cover the latest clinical data and reimbursement progress for the company's existing tests, Epi+Gen CHD™ and PrecisionCHD™, showcasing its innovative capabilities in precision cardiovascular medicine.
- Technology-Driven Approach: Cardio Diagnostics leverages artificial intelligence and genomics to make cardiovascular disease prevention, detection, and management more personalized and precise, further advancing the development and commercialization of clinical tests.
- Risk Factors Disclosure: The company notes in its statement that its future growth strategy may face various known and unknown risks and uncertainties, which could significantly impact its financial performance.
See More
Cardio Diagnostics to Host Investor Conference Call
- Investor Conference Call: Cardio Diagnostics will host an investor conference call on February 18, 2026, at 3 p.m. Central Time, aimed at providing updates on the company's advancements in cardiovascular disease prevention and early detection, particularly regarding its commercially available tests, Epi+Gen CHD™ and PrecisionCHD™.
- Clinical Data Updates: The call will cover recent breakthrough clinical data and reimbursement progress, indicating the company's efforts to enhance the efficiency of cardiovascular disease detection and management through its precision molecular approach.
- Strategic Growth Initiatives: The conference will also discuss the company's strategic growth initiatives, emphasizing its market positioning and future development direction in the field of precision cardiovascular medicine, aimed at attracting more investor interest.
- Webcast Information: Investors can participate via the provided webcast link, while telephone participants should dial the specified numbers and use the provided passcode, ensuring broad dissemination of information and engagement.
See More
Cardio Diagnostics Partners with India to Launch PrecisionCHD Coronary Test
- International Expansion: Cardio Diagnostics has partnered with Aimil Ltd. and Dr. Lal PathLabs Ltd. to introduce the PrecisionCHD coronary test in India, marking the company's first expansion outside the U.S. and targeting a market with rising heart disease rates.
- Technological Innovation: The PrecisionCHD test combines epigenetics, genetics, and AI to detect coronary heart disease at a molecular level from blood samples, addressing the urgent screening demand in urban areas of India where heart disease rates can reach as high as 13%, filling a gap left by traditional angiograms.
- Clinical Integration Progress: The partners have begun integrating the test into Dr. Lal PathLabs' clinical and lab network, with broader commercial deployment expected in 2026 under Indian clinical guidelines, enhancing access to advanced heart diagnostics.
- Executive Insights: Cardio Diagnostics CEO Dr. Meesha Dogan stated that the partnership advances equitable access to cutting-edge cardiovascular care, while Aimil's Executive Director Dr. Mallika Kapoor emphasized that this venture strengthens India's access to advanced heart diagnostics.
See More
Cardio Diagnostics Launches PrecisionCHD Test in India with Aimil and Dr. Lal PathLabs
- Market Expansion: Cardio Diagnostics Holdings partners with Aimil Ltd. and Dr. Lal PathLabs Ltd. to launch the PrecisionCHD test, marking the company's first expansion outside the U.S. and official entry into the Indian market, which is crucial given the rising prevalence of cardiovascular diseases.
- Technological Innovation: The PrecisionCHD test can identify non-obstructive coronary heart disease, surpassing traditional angiography, thereby enabling doctors to provide personalized treatment plans that enhance the quality and effectiveness of healthcare services.
- Commercial Outlook: The test is expected to be commercially launched in 2026, with initial promotion through Dr. Lal PathLabs' laboratory and clinical network, a strategy that will facilitate rapid adaptation to Indian clinical and regulatory protocols, thereby increasing market acceptance.
- Market Reaction: Following the announcement, CDIO's stock surged 29.61% in pre-market trading, indicating a positive market response to this strategic partnership and reflecting investor confidence in the company's future growth potential.
See More
